Baxter spinoff Baxalta officially independent; Cosmo Pharma aims for 163M francs in Cassiopea offering;

@FiercePharma: UPDATED: Bayer, J&J touting Xarelto trial data to counteract Eliquis surge. More | Follow @FiercePharma

@EricPFierce: Join us July 8 for a Twiiter chat on #sustainedrelease with BASF expert Thorsten Cech. Details are here. | Follow @EricPFierce

@CarlyHFierce: Not gonna lie, I purposely use the phrase "the Illinois pharma" every time I write about an Illinois pharma. | Follow @CarlyHFierce

> Baxalta is now officially a standalone company after its $6 billion spinoff from Baxter International ($BAX), with a product line specializing in hemophilia. Report

> Cosmo Pharmaceuticals, in an attempt to raise 163 million Swiss francs, is cutting its stake in the skin and hair treatment company Cassiopea via a public stock offering. Report

> Teva Pharmaceutical ($TEVA) and Philips ($PHG) are together investing up to 100 million shekels ($26.5 million) in medical device and health technology startups in Israel. Report

> Indivior announced a new trial date in a Suboxone patent fight against Watson Laboratories, now Allergan ($AGN), and Par Pharmaceutical. Report

> Johnson & Johnson ($JNJ) cut its carbon emissions in 2014, but it's close to missing its target for water consumption in 2015. Report

> A hotel workers' union started an online campaign to chase pharma funding out of continuing medical education. Report

Medical Device News

@FierceMedDev: UPDATED: American Heart Association guidelines encourage use of stent retrievers to treat stroke. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Pay friends to quit smoking with Pfizer's new digital tool. FiercePharmaMarketing article | Follow @EmilyWFierce

> Feds sentence woman to 97 months in prison for fraudulently billing Medicare for wheelchairs. News

> ViewRay gets $50M in debt to back MRI-guided radiation therapy after IPO withdrawal. Story

Biotech News

@FierceBiotech: FierceBiotech Radio on the cost of CAR-T, the future of Zoetis, and gentrification in Kendall Square. Listen | Follow @FierceBiotech

@JohnCFierce: Trending: Is Celgene killing the traditional biotech partnering formula? Editor's corner | Follow @JohnCFierce

@DamianFierce: Join us as we search for the Amar'e Stoudemire of immuno-oncology. FierceBiotech Radio | Follow @DamianFierce

> Purdue pulls out of FDA panel on abuse-deterrent OxyContin just days before meeting. Report

> Whittled down to biotech size, AstraZeneca's antibiotics crew starts over as Entasis. News

Biotech Research News

> Researchers highlight a nuanced approach to flagging early Alzheimer's. Article

> Antibody 'cocktail' looks promising against deadly Marburg virus. News

> Salk investigators develop a new autophagy combo drug to starve tumors. More

> Dual cancer role for Daple attracts research team at UC San Diego. Article

> UCL team sees promise in mouse study of pancreatic tumor-targeting compound. Story

Diagnostics News

> Cinven snatches up Synlab for $1.96B to beef up in diagnostics. More

> Luxembourg's Eurofins rides JV diagnostics wave with Emory University deal. Editor's corner

> NIH provides Great Basin Scientific and BYU $5M+ to develop rapid test for CRE. Story

> Illumina unveils plans for new European HQ and science center. Item

> Qiagen launches Germany-based JV aimed at companion Dx. Article

Pharma Marketing News

> Feds demand $3.4B in damages, fines in Novartis kickback case. Story

> Latest Sunshine Act bombshell: $6.5B in doc-and-hospital payments last year. More

> House bill would force FDA to ease up on social media. Article

> Pay friends to quit smoking with Pfizer's new digital tool. Story

> Bayer, J&J touting Xarelto trial data to counteract Eliquis surge. Report

And Finally... Oklahoma said it would quickly resume executions after the Supreme Court said it was legal to use a controversial drug in its lethal injections. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.